Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses
Research and development	$ 7,651	$ 3,674	$ 16,874	$ 11,893
General and administrative	2,515	1,152	5,461	2,224
Total operating expenses	10,166	4,826	22,335	14,117
Loss from operations	(10,166)	(4,826)	(22,335)	(14,117)
Other income (expense), net
Foreign exchange transaction gain, net	(1,485)	337	(925)	669
Fair value adjustments on preferred stock tranche obligations		384		1,364
Total other income (expense), net	(1,485)	721	(925)	2,033
Net loss	(11,651)	(4,105)	(23,260)	(12,084)
Dividends on convertible preferred stock	(2,713)	(1,401)	(7,648)	(4,159)
Net loss attributable to common stockholders	$ (14,364)	$ (5,506)	$ (30,908)	$ (16,243)
Net loss per common share, basic and diluted	$ (55.25)	$ (21.18)	$ (118.89)	$ (62.48)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	259,966	259,966	259,966	259,966
Other comprehensive loss
Net loss	$ (11,651)	$ (4,105)	$ (23,260)	$ (12,084)
Currency translation	2,331	(2,059)	2,136	(2,140)
Total comprehensive loss	$ (9,320)	$ (6,164)	$ (21,124)	$ (14,224)